David Hay — Friday POW!: Travelers (TRV)
A "defensive" P&C insurer that has compounded like a growth stock — repriced to rate adequacy (22.7% core ROE), with a $106B bond float earning a rising tail and ~20% capital return, yet trading ~10.8× NTM, a discount to peers.
One-line take: This week's POW! pick is Travelers (TRV), rated a Buy for long-term compounder investors — a property-casualty insurer that has repriced its entire book to "rate adequacy" (22.7% trailing core ROE, 85.3% underlying combined ratio), earns a rising tail on a $106B fixed-income float in a higher-for-longer world ($3.3B after-tax investment income guided for 2026), and returns capital at a ~20% annualized yield on a ~$46B cap (14% dividend raise, the 14th straight year). It trades at ~10.8× NTM earnings — a discount to peers Chubb (12.3×) and Progressive (12.8×) despite a higher ROE — with a re-rate toward ~13× the upside case. Haymaker ties the demand to its "three-cycle regime" (debt-supercycle unwind, globalization reversal/reshoring, energy constraint). A Barclays Underweight downgrade (Jun 12) at the 52-week high is the main bear case; Haymaker frames a likely ~5% pullback off the high as a more aggressive entry. A long-term hold, not a trade.
1. Stocks & names mentioned
| Ticker | Name | Research | View | What he said | At |
|---|
| TRV | The Travelers Companies | QT · SA · STK · FA | Positive | Pick of the Week — a Buy for long-term compounders. Q1 2026 core EPS $7.71 vs $7.08 est (+9% beat), revenue $11.92B (+7.4%), 19.7% ROE; FY2025 net written premium $43.6B, net income $6.3B (+25.8%), TTM core ROE 22.7%, combined ratio 88.6% / underlying 85.3%. Has repriced its whole book to "rate adequacy." A $106B investment portfolio (90%+ high-quality fixed income) earns a rising tail in a higher-for-longer world ($3.3B after-tax NII guided 2026). Capital return ~20% annualized on a ~$46B cap ($2.2B returned in Q1, dividend +14% — 14th straight year). AI/automation real: >half of claims straight-through, expense ratio −300bp since 2016 (~$430M/yr), $13B tech spend, 65B proprietary data points. ~10.8× NTM P/E vs Chubb 12.3× / Progressive 12.8× despite a higher ROE; re-rate toward ~13× the upside. Barclays cut to Underweight Jun 12 (main bear case) but the stock sits at a 52-week high; a likely ~5% pullback is a more aggressive entry. A long-term hold, not a trade. | read |
| CB | Chubb | QT · SA · STK · FA | Neutral | Valuation comp only — trades ~12.3× NTM earnings / ~1.64x P/B, a premium to Travelers despite TRV's higher 22.7% core ROE. Chubb's international diversification and high-net-worth brand partly explain its multiple. Cited to frame the TRV discount, not an argued call on CB. | read |
| PGR | Progressive | QT · SA · STK · FA | Neutral | Valuation comp only — trades ~12.8× NTM / ~3.92x P/B at an exceptional ~38% ROE; its premium multiple reflects that ROE and a more stable personal-auto book (vs TRV's catastrophe-driven volatility). The gap to PGR's multiple is what Haymaker argues the market hasn't yet given TRV credit for. A reference, not a call on PGR. | read |
References only (not tickers): the Reshoring Initiative (source of the $1.6T reshoring figure), Evergreen Gavekal, Bloomberg, CoStar, and the Barclays / Roth Capital / Keefe Bruyette / Piper Sandler / Argus analyst desks cited on valuation.
2. Talking points
Background — a defensive insurer compounding like a growth stock
- The second-largest US personal-lines insurer and the dominant commercial-lines underwriter; $43.6B net written premium and $6.3B net income in FY2025, $7.4B returned to shareholders. The stock is ~$320, up ~91% over three years and 135% over five.
- The framing question: in Q1 2026 TRV posted record-ish core income ($1.7B, EPS $7.71 vs $7.08, a 9% beat), raised the dividend 14% and returned $2.2B — yet the stock rose less than 1%. When a company posts a top quarter and the market shrugs, is this the right entry or is patience warranted?
Travelers as an AI trailblazer
- One of the few companies showing AI producing tangible bottom-line results today: >half of all claims now eligible for straight-through digital processing (1.5M claims in 2025), driving "significant annual run-rate cost savings."
- Expense ratio cut 300bp since 2016 (~$430M/yr at current premium), $13B invested in tech since 2016, 65 billion proprietary data points — the training asset a new entrant can't replicate. FY2025 underwriting income >$3.4B, +40% YoY. CEO Schnitzer: "still early in this transformation" — Haymaker reads the current ratios as the floor, not the ceiling.
The repricing cycle — and why it's not over
- The P&C industry deteriorated from 2020 on three forces: catastrophe losses, inflation (replacement costs), and social inflation (litigation). TRV responded with systematic, aggressive repricing across every line rather than letting losses compound.
- That repricing has now reached "rate adequacy" across virtually every state and line. Q1 2026: Business Insurance renewal premium change +6.1% (~8% ex-property) at 85% retention; Personal Insurance "caught up on insurance to value." The book is now priced for the current loss environment, with the 85.3% underlying combined ratio leaving margin.
The $106B float in a higher-for-longer world
- P&C insurers invest the float between premium collection and claims payment; the after-tax return on it tracks the rate environment. The 2012–2022 zero-rate decade was a structural headwind — float that should earn 4–5% earned next to nothing.
- The 2022 rate reset flipped that into a tailwind. On effectively the largest bond portfolio of any US P&C insurer (90%+ high-quality fixed income), even small yield gains move earnings: net investment income is guided to $3.3B after tax in 2026, ramping ~$800M in Q1 to ~$870M in Q4. If higher-for-longer holds, this engine compounds for years.
Three-cycle regime = a structural tailwind
- Globalization reversal is the most direct demand driver: every company reshoring supply chains and building domestic facilities buys commercial insurance — supply-chain cover, product liability, D&O, surety bonds, workers' comp. The Reshoring Initiative's $1.6T of announced reshoring since 2020 lands in exactly TRV's strongest lines.
- Energy-security spend (oil & gas, grid/nuclear, transition infrastructure) feeds specialty and environmental lines; the debt-supercycle unwind drives institutional-liability demand (banks, asset managers, refinancing risk) into TRV's specialty book — and higher rates lift the float income at the same time.
Valuation — a discount to Chubb and Progressive
- ~10.8× NTM earnings (near the low end of the five-year range) vs Chubb 12.3× and Progressive 12.8× — both at premiums despite TRV's 22.7% core ROE topping both peers.
- On book value, TRV's ~2.6× P/B sits between Chubb's 1.64× and Progressive's 3.92× (PGR's premium reflects ~38% ROE). Haymaker thinks the market isn't yet pricing the durability of TRV's ROE — skepticism it calls "a bit overdone" given rate adequacy, the rate-driven investment tailwind, and favorable commercial pricing. (Side note: P/S matters less for financials.)
Capital return — ~20% annualized and a 14th dividend hike
- $7.4B returned in FY2025 and $2.2B in Q1 2026 alone — an annualized pace approaching $9B, a ~20% capital-return yield on the ~$46B cap, via dividends plus buybacks ($1.8B authorized for Q1) that shrink share count while EPS grows.
- The 14% dividend raise marks the 14th consecutive year of dividend growth.
Technicals — buying at a 52-week high
- Trading at/near its 52-week high ($249.19–$321.08 range); the concern is the easy money is made. The counter: a stock at this level on record earnings, a 9% beat, a 14% raise and $2.2B of buybacks is at its high because the business is performing. Next catalyst is Q2 earnings in July (a similar setup; Q2 cat season historically more benign than Q1).
- A multi-year, earnings-driven up-trend; on its history a ~5% pullback "seems likely before too long." Risk-averse investors may wait or start with a small position. Profits have more than doubled off the 2022 base, yet at ~11× earnings "there's very little growth being priced in."
Arguing the other side — Barclays, catastrophes, El Niño
- The Barclays downgrade to Underweight (Jun 12, 2026) is the most current, credible bear case: at a 52-week high, the worry is the valuation has fully discounted the repricing cycle, cat losses normalize upward from benign Q1 levels, and the multiple premium isn't sustainable as growth moderates — i.e., fairly valued / modestly stretched, not deteriorating.
- Catastrophe exposure is the model's most unpredictable element — one hurricane/wildfire/storm season can swing a quarter regardless of underlying quality, and a looming "Super El Niño" could mean heavier industry losses over the next 12 months. TRV isn't immune but manages it well over time.
The bottom line — "what are we actually buying?"
- The standard Haymaker query: a dominant P&C franchise off its strongest quarter on record, book repriced to rate adequacy, a $106B portfolio earning $3.3B after-tax and ramping, in the most favorable macro regime for P&C since the early 2000s — returning $2.2B in a quarter while beating by 9% and raising the dividend for a 14th year; a Dow component with 135% five-year returns the market calls "defensive."
- Recommended as a Buy for long-term compounder investors; Haymaker expects a re-rate to ~13× forward (a level repeatedly hit recently) and would use a probable retracement to "more aggressively buy up this name." Not priced for perfection at 10.8×.
3. In plain English
TRV — The Travelers Companies Positive
Travelers is one of America's biggest property-and-casualty insurers — it writes the home, auto, business and specialty policies that pay out when something goes wrong. Two things make Haymaker like it right now. First, "rate adequacy": after years of catastrophe and inflation losses, the company has methodically re-priced almost every policy so the premiums it charges finally match the risks it takes — that's why it earns a 22.7% return on equity (one of the best in the industry) with lots of margin to spare. Second, the "float": insurers collect premiums today and pay claims later, and they invest the cash in between. Travelers sits on a $106 billion mostly-bond portfolio, and in a world where interest rates stay higher for longer, that pile now throws off a growing river of income (guided to $3.3 billion after tax this year) that was earning almost nothing during the zero-rate decade.
On top of that, the company hands shareholders roughly 20% of its market value back every year through dividends and buybacks (it just raised the dividend 14%, the 14th year in a row), yet the stock trades at only ~10.8× next year's earnings — cheaper than rivals Chubb and Progressive even though it out-earns them. Haymaker's view is simple: this is a high-quality "compounder" being priced like a boring, fully-valued utility, and it should drift up toward a ~13× multiple over time. The catch is that one bad hurricane season can dent any quarter, and a Wall Street desk (Barclays) just turned cautious with the stock at a 52-week high — so a ~5% dip is likely, and Haymaker would use it to buy more aggressively. This is a long-term hold to compound with, not a quick trade.
Summary derived from the paid Haymaker newsletter (text in transcript.txt) for personal study. Not investment advice. © Haymaker / David Hay for source material.